RESUMO
Fifty-six patients with chronic allergic rhinitis were selected for a randomized double-blind study comparing oxatomide with a placebo. At the end of the 1-month treatment period symptoms had disappeared or were markedly improved in 81% of the oxatomide-treated patients compared with only 17% of the placebo group. Therapeutic control was achieved in most patients with a dose of 30 mg bid. Improvements were characterized by a reduction in the number, duration and severity of episodes of rhinitis. Oxatomide also significantly reduced the requirements of patients for additional antiallergic medication. No significant side effects were reported.
Assuntos
Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Piperazinas/uso terapêutico , Rinite Alérgica Perene/tratamento farmacológico , Adolescente , Adulto , Idoso , Criança , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Ninety-one hay fever patients received either 0.5 mg/kg oxatomide b.i.d. or 0.4 mg/kg diphenhydramine b.i.d. in a two-month double-blind study. If necessary this dose could be doubled. The results showed that fewer oxatomide patients needed to double this starting dose and to use a nasal spray. Oxatomide proved to be more effective than diphenhydramine in limiting the severity of the hay fever attacks, as evidenced by the findings that oxatomide patients had fewer complaint-days, and that more of these patients were rated by the investigators to have excellent or good results. Apart from daytime fatigue, transient in several patients, no oxatomide-induced side-effects were found.
